Ranimustine

Ranimustine is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia and polycythemia vera.
It has never been filed for FDA evaluation in the United States, where it is not marketed.

Synthesis

Ranimustine is made by reacting the primary amine of a pyranose sugar with o-nitrophenyl N--N-nitrosocarbamate to form the nitrosourea group.